Company intelligence / Profile preview

Ex Stylus

Cambridge, Massachusetts, United Statesepson.ca ↗

Ownership: Private
Employees: ~40
Development stage: Other

Overview

Stylus Medicine has developed a novel in vivo gene editing platform using engineered recombinases and cell-targeted lipid nanoparticles. Their approach enables precise, durable integration of large therapeutic payloads directly into patient immune cells, aiming to simplify and scale CAR-T therapies. The company is currently preclinical, with first data from a single-dose CD3-targeted LNP-CAR program expected at ASGCT 2025.

Therapeutic areas: OncologyRare DiseasesImmunology
Modalities: Gene therapyLipid nanoparticle delivery therapyRecombinase-based therapy
Industry: Biotech

Beyond the preview

Go deeper on Ex Stylus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ex Stylus.

Explore the full profile